€52.50
2.34% yesterday
Xetra, Dec 23, 05:35 pm CET
ISIN
DE000A1EWVY8
Symbol
FYB
Index
Sector
Industry

Formycon Stock price

€52.50
+4.45 9.26% 1M
-2.20 4.02% 6M
-3.90 6.91% YTD
-1.30 2.42% 1Y
-6.50 11.02% 3Y
+21.70 70.45% 5Y
+42.52 426.05% 10Y
Xetra, Closing price Mon, Dec 23 2024
+1.20 2.34%
ISIN
DE000A1EWVY8
Symbol
FYB
Index
Sector
Industry

Key metrics

Market capitalization €927.38m
Enterprise Value €897.61m
P/E (TTM) P/E ratio 13.03
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 14.76
P/S ratio (TTM) P/S ratio 15.25
P/B ratio (TTM) P/B ratio 1.61
Revenue growth (TTM) Revenue growth -11.42%
Revenue (TTM) Revenue €60.80m
EBIT (operating result TTM) EBIT €-24.60m
Free Cash Flow (TTM) Free Cash Flow €-33.71m
EPS (TTM) EPS €4.03
P/E forward negative
P/S forward 15.36
EV/Sales forward 14.87
Show more

Is Formycon a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.

Formycon Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Formycon forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a Formycon forecast:

Buy
100%

Financial data from Formycon

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
61 61
11% 11%
100%
- Direct Costs 53 53
20% 20%
88%
7.58 7.58
69% 69%
12%
- Selling and Administrative Expenses 16 16
46% 46%
27%
- Research and Development Expense 14 14
3% 3%
23%
-23 -23
2,025% 2,025%
-37%
- Depreciation and Amortization 2.06 2.06
13% 13%
3%
EBIT (Operating Income) EBIT -25 -25
752% 752%
-40%
Net Profit 64 64
251% 251%
105%

In millions EUR.

Don't miss a Thing! We will send you all news about Formycon directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Formycon Stock News

EQS
15 days ago
Über Formycon: Die Formycon AG (FWB: FYB) ist ein führender, unabhängiger Entwickler von hochwertigen Biosimilars, Nachfolgeprodukten biopharmazeutischer Arzneimittel. Das Unternehmen fokussiert sich auf Therapien in der Ophthalmologie, Immunologie, Immun-Onkologie sowie weiteren wichtigen Indika...
EQS
19 days ago
Die Formycon AG (FWB: FYB) ist ein führender, unabhängiger Entwickler von hochwertigen Biosimilars, Nachfolgeprodukten biopharmazeutischer Arzneimittel. Das Unternehmen fokussiert sich auf Therapien in der Ophthalmologie, Immunologie, Immun-Onkologie sowie weiteren wichtigen Indikationsgebieten u...
AD HOC NEWS
19 days ago
Formycon AG / DE000A1EWVY8
More Formycon News

Company Profile

Formycon AG engages in the manufacture of biosimilar drugs and formulations. Its product candidates include FYB201, FYB202, FYB203, and FYB205 which focusoin the opthalmology and immunology disease areas. The company was founded by Friedrich Wilhelm Steinweg and Nicolas Combé in 2007 and is headquartered in Munich, Germany.

Head office Germany
CEO Stefan Glombitza
Employees 238
Founded 2007
Website formycon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today